The presymptomatic phase of Alzheimer disease (AD) starts with the deposition of amyloid-β
in the cortex and begins a decade or more before the emergence of cognitive decline. The …

Early Alzheimer's disease (AD) is associated with hippocampal hyperactivity and decreased
sleep quality. Here we show that homeostatic mechanisms transiently counteract the …

Early detection of Alzheimer's disease (AD) is essential for improving the patients outcomes
and advancing our understanding of disease, allowing for timely intervention and treatment …

The mechanisms that confer cognitive resilience to Alzheimer's Disease (AD) are not fully
understood. Here, we describe a neural circuit mechanism underlying this resilience in a …

Alzheimer's disease (AD) is increasingly seen as a disease of synapses and diverse
evidence has implicated the amyloid-β peptide (Aβ) in synapse damage. The molecular and …

Hyperactivity mediated by synaptotoxic β-amyloid (Aβ) oligomers is one of the earliest forms
of neuronal dysfunction in Alzheimer's disease. In the search for a preventive treatment …

The Alzheimer's disease-associated peptide amyloid-beta (Aβ) has been associated with
neuronal hyperactivity under anesthesia, but clinical trials of anticonvulsants or neural …

Objective. Ultrasound neuromodulation has become an emerging method for the therapy of
neurodegenerative and psychiatric diseases. The phased array ultrasonic transducer …

Evidence suggests that impaired synaptic and firing homeostasis represents a driving force
of early Alzheimer's disease (AD) progression. Here, we examine synaptic and sleep …

Anesthesia is a powerful tool in neuroscientific research, especially in sleep research where
it has the experimental advantage of allowing surgical interventions that are ethically …